Difficult asthma or Churg-Strauss syndrome?BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7182.475 (Published 20 February 1999) Cite this as: BMJ 1999;318:475
Steroids may be masking undiagnosed cases of Churg-Strauss syndrome
- David P D'Cruz, Senior lecturer in rheumatology (D.P.Cruz@mds.qmw.ac.uk),
- Neil C Barnes, Consultant physician in respiratory medicine,
- C Martin Lockwood, Reader in therapeutic immunology
- School of Clinical Medicine, Addenbrooke's Hospital, Cambridge CB2 2QQ
The standard management of asthma with inhaled corticosteroids and bronchodilators works in most patients. A significant minority, however, respond poorly to these medications and require frequent intermittent courses of oral corticosteroids or occasionally long term oral corticosteroid treatment. The success of the new leukotriene antagonists in reducing the need for steroids in these patients with difficult asthma seems also to be unmasking some undiagnosed cases of Churg-Strauss syndrome, the symptoms of which were apparently being controlled by steroids.
The pathophysiology of bronchoconstriction is not fully understood, but it is clear that leukotrienes, pro-inflammatory mediators arising from arachidonic acid, are important in the inflammatory processes of asthma. Several pharmacological agents, including the sulfidopeptide-leukotriene antagonists zafirlukast, montelukast, and pranlukast, have been studied in large scale randomised clinical trials.1 These trials have all been in patients with mild to moderate asthma who were not taking oral corticosteroids —or, if they were, the dose was not altered during the studies. Several cases of Churg-Strauss syndrome associated with the useof zafirlukast have been reported in the United States and more recently with montelukast in the United Kingdom.2 3
Churg-Strauss syndrome is a rare allergic granulomatous eosinophilic vasculitis characterised by …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.